220 related articles for article (PubMed ID: 32692906)
41. Oridonin enhances TRAIL-induced apoptosis through GALNT14-mediated DR5 glycosylation.
Jeon MY; Seo SU; Woo SM; Min KJ; Byun HS; Hur GM; Kang SC; Kwon TK
Biochimie; 2019 Oct; 165():108-114. PubMed ID: 31336136
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of TACE activity enhances the susceptibility of myeloma cells to TRAIL.
Kagawa K; Nakano A; Miki H; Oda A; Amou H; Takeuchi K; Nakamura S; Harada T; Fujii S; Yata K; Ozaki S; Matsumoto T; Abe M
PLoS One; 2012; 7(2):e31594. PubMed ID: 22389670
[TBL] [Abstract][Full Text] [Related]
43. Germline
Erger F; Aryal RP; Reusch B; Matsumoto Y; Meyer R; Zeng J; Knopp C; Noel M; Muerner L; Wenzel A; Kohl S; Tschernoster N; Rappl G; Rouvet I; Schröder-Braunstein J; Seibert FS; Thiele H; Häusler MG; Weber LT; Büttner-Herold M; Elbracht M; Cummings SF; Altmüller J; Habbig S; Cummings RD; Beck BB
Proc Natl Acad Sci U S A; 2023 May; 120(22):e2211087120. PubMed ID: 37216524
[TBL] [Abstract][Full Text] [Related]
44. Truncated O-glycans promote epithelial-to-mesenchymal transition and stemness properties of pancreatic cancer cells.
Thomas D; Sagar S; Caffrey T; Grandgenett PM; Radhakrishnan P
J Cell Mol Med; 2019 Oct; 23(10):6885-6896. PubMed ID: 31389667
[TBL] [Abstract][Full Text] [Related]
45. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
[TBL] [Abstract][Full Text] [Related]
46. Aclarubicin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis through death receptor 5 upregulation.
Horinaka M; Yoshida T; Nakata S; Shiraishi T; Tomosugi M; Yoshikawa S; Wakada M; Sakai T
Cancer Sci; 2012 Feb; 103(2):282-7. PubMed ID: 22077238
[TBL] [Abstract][Full Text] [Related]
47. A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase.
Ju T; Cummings RD
Proc Natl Acad Sci U S A; 2002 Dec; 99(26):16613-8. PubMed ID: 12464682
[TBL] [Abstract][Full Text] [Related]
48. Lipocalin 2 inversely regulates TRAIL sensitivity through p38 MAPK-mediated DR5 regulation in colorectal cancer.
Kim SL; Min IS; Park YR; Lee ST; Kim SW
Int J Oncol; 2018 Dec; 53(6):2789-2799. PubMed ID: 30221676
[TBL] [Abstract][Full Text] [Related]
49. BCR-ABL regulates death receptor expression for TNF-related apoptosis-inducing ligand (TRAIL) in Philadelphia chromosome-positive leukemia.
Kuroda I; Inukai T; Zhang X; Kikuchi J; Furukawa Y; Nemoto A; Akahane K; Hirose K; Honna-Oshiro H; Goi K; Kagami K; Yagita H; Tauchi T; Maeda Y; Sugita K
Oncogene; 2013 Mar; 32(13):1670-81. PubMed ID: 22665066
[TBL] [Abstract][Full Text] [Related]
50. Cosmc-dependent mucin-type
Stotter BR; Talbot BE; Capen DE; Artelt N; Zeng J; Matsumoto Y; Endlich N; Cummings RD; Schlondorff JS
Am J Physiol Renal Physiol; 2020 Feb; 318(2):F518-F530. PubMed ID: 31904283
[TBL] [Abstract][Full Text] [Related]
51. Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation.
Kim EH; Yoon MJ; Kim SU; Kwon TK; Sohn S; Choi KS
Cancer Res; 2008 Jan; 68(1):266-75. PubMed ID: 18172319
[TBL] [Abstract][Full Text] [Related]
52. Gefitinib enhances human colon cancer cells to TRAIL-induced apoptosis of via autophagy- and JNK-mediated death receptors upregulation.
Chen L; Meng Y; Guo X; Sheng X; Tai G; Zhang F; Cheng H; Zhou Y
Apoptosis; 2016 Nov; 21(11):1291-1301. PubMed ID: 27629794
[TBL] [Abstract][Full Text] [Related]
53. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
Gómez-Benito M; Martinez-Lorenzo MJ; Anel A; Marzo I; Naval J
Exp Cell Res; 2007 Jul; 313(11):2378-88. PubMed ID: 17462628
[TBL] [Abstract][Full Text] [Related]
54. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling.
Kelley RF; Totpal K; Lindstrom SH; Mathieu M; Billeci K; Deforge L; Pai R; Hymowitz SG; Ashkenazi A
J Biol Chem; 2005 Jan; 280(3):2205-12. PubMed ID: 15520016
[TBL] [Abstract][Full Text] [Related]
55. Stable expression of sialyl-Tn antigen in T47-D cells induces a decrease of cell adhesion and an increase of cell migration.
Julien S; Lagadec C; Krzewinski-Recchi MA; Courtand G; Le Bourhis X; Delannoy P
Breast Cancer Res Treat; 2005 Mar; 90(1):77-84. PubMed ID: 15770530
[TBL] [Abstract][Full Text] [Related]
56. Azithromycin enhances anticancer activity of TRAIL by inhibiting autophagy and up-regulating the protein levels of DR4/5 in colon cancer cells in vitro and in vivo.
Qiao X; Wang X; Shang Y; Li Y; Chen SZ
Cancer Commun (Lond); 2018 Jul; 38(1):43. PubMed ID: 29970185
[TBL] [Abstract][Full Text] [Related]
57. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer.
Ozawa F; Friess H; Kleeff J; Xu ZW; Zimmermann A; Sheikh MS; Büchler MW
Cancer Lett; 2001 Feb; 163(1):71-81. PubMed ID: 11163110
[TBL] [Abstract][Full Text] [Related]
58. Tunicamycin enhances human colon cancer cells to TRAIL-induced apoptosis by JNK-CHOP-mediated DR5 upregulation and the inhibition of the EGFR pathway.
Guo X; Meng Y; Sheng X; Guan Y; Zhang F; Han Z; Kang Y; Tai G; Zhou Y; Cheng H
Anticancer Drugs; 2017 Jan; 28(1):66-74. PubMed ID: 27603596
[TBL] [Abstract][Full Text] [Related]
59. CRISPR-screen identifies ZIP9 and dysregulated Zn2+ homeostasis as a cause of cancer-associated changes in glycosylation.
Rømer TB; Khoder-Agha F; Aasted MKM; de Haan N; Horn S; Dylander A; Zhang T; Pallesen EMH; Dabelsteen S; Wuhrer M; Høgsbro CF; Thomsen EA; Mikkelsen JG; Wandall HH
Glycobiology; 2023 Oct; 33(9):700-714. PubMed ID: 36648436
[TBL] [Abstract][Full Text] [Related]
60. Vernodalol enhances TRAIL-induced apoptosis in diffuse large B-cell lymphoma cells.
Wu W; Yang Y; Deng G; Ma L; Wei G; Zheng G; Han X; He D; Zhao Y; He J; Cai Z; Yu R
Mol Carcinog; 2017 Oct; 56(10):2190-2199. PubMed ID: 28467689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
